Melatonin’s Preservation of Sleep Architecture

Effects in Elderly Patients

• In elderly individuals, a 2 mg prolonged‑release melatonin formulation produced only minimal objective changes in sleep‑stage distribution (N1, N2, N3, REM) compared with baseline, indicating preservation of normal sleep architecture. Evidence level: moderate (clinical trial). [1][2]

Dose‑Related Pharmacodynamics

• Oral melatonin doses ≥ 10 mg are associated with melatonin‑receptor desensitization, leading to pharmacologic effects that extend beyond simple circadian signaling. Evidence level: expert opinion / guideline. 3

Timing for Chronobiotic and Sleep‑Promoting Effects

• Administering melatonin 1.5–2 hours before the desired sleep onset time optimizes both its chronobiotic action on the suprachiasmatic nucleus and its sleep‑promoting effect, particularly in patients with circadian‑rhythm disorders. Evidence level: expert consensus. 4

Comparison with Other Sedatives

• Unlike dexmedetomidine, which has been shown to preserve sleep architecture in intensive‑care settings, melatonin’s architecture‑preserving properties have been documented primarily in healthy individuals receiving physiologic doses (0.3–1 mg). Evidence level: moderate (comparative study). 5